The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

Ph.D., Chief Research & Development Officer at Nektar. "These findings further validate our therapeutic approach of using a Treg stimulator to dampen inflammatory responses and simultaneously ...

The sophomore is said to have been left unhappy after recently being demoted to a reserve role on his team, which led to him skipping multiple practice sessions.

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) has announced results from two Phase 1b studies, published in Nature Communications, showing the efficacy of rezpegaldesleukin in treating atopic ...

No races have been called yet. Stay tuned for the latest updates regarding the election results.